Remix Therapeutics Merges with Passage Bio for $100M

Remix Therapeutics, Inc. is set to merge with Passage Bio, Inc. in a reverse merger arrangement, valued at approximately $100 million. This strategic move is designed to leverage Remix's RNA medicine platform to expedite the development of innovative small molecule therapies that focus on RNA processing. The transaction seeks to reposition Passage Bio from its current gene therapy activities to a broader involvement in RNA-targeted therapeutics.

Under the terms of the all-stock merger agreement, shareholders of Passage Bio will own around 7% of the newly formed entity, while Remix Therapeutics shareholders will hold the remaining 93%, indicative of a significant shift in control. The deal coincides with a separate private placement by Remix, anticipated to raise at least $100 million. Collectively, these funds, alongside existing cash reserves, aim to sustain the merged company's operations until 2028. Remix's CEO, Peter Smith, Ph.D., will spearhead the leadership of the combined enterprise, which will be rebranded as Remix Therapeutics and will trade under the ticker "RMTX" on Nasdaq. Additionally, Passage Bio investors will receive one non-tradeable contingent value right per share aligned with potential future proceeds from out-licensed assets.

The merger represents a strategic pivot, positioning Passage Bio's existing cash and public listing status as a vehicle for Remix's ambitious RNA oncology endeavors. An assigned equity value of $226 million for Remix contrasts sharply with Passage Bio's valuation of approximately $20 million, which underlines the substantial equity dilution for Passage Bio shareholders. Remix's ongoing development of REM-422, which has shown promise with a 43% objective response rate and 100% disease control rate in certain cancers, potentially benefits from this fresh influx of capital.

This deal underlines a broader trend in the biotechnology sector where companies are increasingly partnering or merging to gain access to novel technologies and platforms. In doing so, Remix strengthens its capacity to progress its pipeline without immediate financial strains, while Passage Bio redirects its strategic focus from gene therapy, having terminated agreements including its collaboration with Catalent and the University of Pennsylvania in this domain.

Moving forward, the merger’s success hinges on meeting closing conditions and raising the expected private placement funds. In addition, the typical clinical and regulatory risks associated with developing new therapies, particularly those involving novel RNA-targeted small molecules, remain a critical consideration as the combined entity navigates through upcoming milestones.